MRD detectability stratifies patients by risk of progression. (A-D) Progression-free survival (PFS) for patients from the longitudinal cohort stratified by MRD at baseline, post-radiotherapy (RT), mid-chemotherapy, and end-of-therapy. (E-H) PFS for patients from the longitudinal cohort stratified by MRD and clinical risk group at the respective time-points. See also Figures S3 and S4. AR, average-risk; CI, confidence interval; HR, high-risk; neg, negative; pos, positive.